Based on these observations, the KRAS/PIK3CA MT molecular subtype was identified as one of particular interest in the evaluation of alisertib and TAK-733, and a total of nine double-mutant colorectal cancer cell lines were selected for further assessment (Figure 1B). The gene discussed is KRAS; the disease is colorectal cancer.